U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Warrior Families: Advancing Regenerative Medicine Through Science - 10/05/2023
  1. FDA Meetings, Conferences and Workshops

Outreach | On-Demand

Event Title
Warrior Families: Advancing Regenerative Medicine Through Science
October 5, 2023

Date:
October 5, 2023
Time:
11:00 AM - 12:15 PM ET

The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) hosted a public virtual webinar on Thursday, October 5th from 11:00 a.m. – 12:15 p.m. ET. The webinar, Warrior Families: Advancing Regenerative Medicine Through Science, featured a panel of families who shared their experiences with advocacy and contributing to therapeutic product development for loved ones living with rare diseases.

Warrior Families: Advancing Regerative Medicine Through Science Event

Event Details

The webinar featured a panel of families of individuals with rare diseases:

  • How to support therapeutic product development through natural history studies, clinical trials, animal models, and other research activities.   

  • How to connect with researchers, industry, and other partners to advance the state of the science in the face of limited treatment options. 

Meeting Materials

View a recording of the webinar here.

What is Regenerative Medicine?

Regenerative medicine therapies, such as cell and gene therapies, hold promise for transforming medicine and creating options for patients living with difficult, rare, and often incurable diseases. The FDA plays a vital role in facilitating the development of regenerative medicine therapies, as well as in ensuring approved products are safe and effective for patients.

About the RegenMedEd Series

This webinar was part of an educational series, RegenMedEd: An FDA CBER OTP Series on Regenerative Medicine. The RegenMedEd series aims to bring together important stakeholders and FDA staff to discuss foundational information about regenerative medicine therapies, such as gene therapy and cell therapy products, and explore opportunities for patients, caregivers, and advocates to engage with FDA to help advance drug development. 

You can access previous RegenMedEd event materials, including event recordings and transcripts, here: https://www.fda.gov/news-events/otp-events-meetings-and-workshops. 
 

Back to Top